A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease
The primary purpose of this study was to assess the safety and tolerability of lucerastat in
adults with Fabry Disease receiving Enzyme Replacement Therapy (ERT).
The secondary objectives were to investigate the effects of lucerastat on plasma and urine
levels of biomarkers, to assess its effects on renal and cardiac functions and to determine
the pharmacokinetic profile of lucerastat at steady-state.
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lucerastat (CDP923) After Multiple Dosing in Healthy Subjects
The objectives of this study were to evaluate the safety and tolerability of lucerastat and
to determine its pharmacokinetic profile after multiple dosing. Also, the potential effect
of food on the pharmacokinetics of lucerastat was explored following a single dose of 500
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.